时间：2026年8月23日
Date: Aug 23, 2026
Rznomics入驻礼来San Diego创新实验室（Lilly Gateway Labs），把韩国”反式剪接核酶”RNA平台直接送进美国大药厂”后花园”
Rznomics Enters Lilly Gateway Labs in San Diego to Fast-Track Its Trans-Splicing Ribozyme Platform—Korean RNA Bet Lands Inside Big Pharma’s Backyard
摘要 :
2026年8月23日，处于临床阶段的韩国生物制药公司Rznomics宣布正式入驻美国礼来San Diego创新实验室（Lilly Gateway Labs，LGL）——LGL是礼来Catalyze360创新生态的重要组成部分——旨在加速其自研”反式剪接核酶（trans-splicing ribozyme）”RNA编辑平台的研发。
入驻LGL后，Rznomics将获得”即插即用”的湿实验室设施，并以结构化方式接触到礼来的科研人员、高管团队及Catalyze360合作网络，同时保留自主研发方向。此次动作是2025年5月双方签署研究合作、以及Rznomics于2025年12月完成KOSDAQ上市（代码476830）之后的下一步。核心管线RZ-001已获FDA针对肝细胞癌（HCC）的再生医学先进疗法（RMAT）资格认定，将继续推进临床开发；公司还计划利用其覆盖200多种疾病的靶点基因数据库加速新分子发现，并扩展全球临床基础设施与合作。CEO李成旭表示，进入LGL是”Rznomics自研RNA平台的一个重要里程碑”，标志着公司同时获得美国本土的物理据点与礼来RNA疗法战略的更深协同。
Summary :
Clinical-stage South Korean biopharma Rznomics Inc. announced on August 23, 2026 that it has joined Lilly Gateway Labs (LGL) in San Diego, part of Eli Lilly’s Catalyze360 innovation ecosystem, to accelerate development of its proprietary trans-splicing ribozyme RNA-editing platform.
Membership in LGL gives Rznomics turn-key wet-lab facilities plus structured access to Lilly scientists, executives and the Catalyze360 partner network, while preserving Rznomics’s independent research direction. The move builds on a May 2025 research collaboration with Lilly and follows Rznomics’s December 2025 KOSDAQ listing (ticker 476830). Lead asset RZ-001—recently granted FDA Regenerative Medicine Advanced Therapy (RMAT) designation for hepatocellular carcinoma—will continue in clinical development, while the company plans to leverage its target-gene database covering more than 200 diseases to accelerate discovery and expand global clinical infrastructure and partnerships. CEO Seong-Wook Lee called the LGL entry “a meaningful milestone for Rznomics’ proprietary RNA platform,” signaling both a physical U.S. footprint and deeper strategic alignment with Lilly’s RNA-therapeutics ambitions.
入选理由 :
罕见的”韩国小盘RNA平台公司直接物理入驻美国大药厂研发园区”节点——极其直观地展示了礼来Catalyze360模式如何以”不并购”的方式锁定RNA编辑赛道的优先看货权，也是亚洲生物科技公司”向西输出平台”的清晰读数。
Why Selected:
A rare “small-cap Korean RNA platform physically embedded inside Big Pharma’s U.S. campus” moment—the most concrete read on how the Catalyze360 model lets Lilly buy first-look optionality on RNA editing without acquiring it, and how Asian biotech is exporting platforms westward.
浏览量：152,300
Views：152,300
独立IP：44,900
Unique Clicks ：44,900
